Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

被引:1
|
作者
Caro, Jessica [1 ]
Cairns, David [2 ]
Menzies, Tom [2 ]
Boyle, Eileen [1 ]
Pawlyn, Charlotte [3 ]
Cook, Gordon [2 ]
Kaiser, Martin [3 ]
Walker, Brian A. [4 ]
Owen, Roger [5 ]
Jackson, Graham H. [6 ]
Morgan, Gareth J. [1 ]
Heaney, Jennifer [7 ]
Drayson, Mark [7 ]
Davies, Faith E. [1 ]
机构
[1] NYU Langone Hlth, Perlmutter Canc Ctr, 168 E 34th St, New York, NY 10016 USA
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England
[3] Inst Canc Res, London, England
[4] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[5] St James Univ Hosp, Leeds, W Yorkshire, England
[6] Newcastle Univ, Dept Hematol, Newcastle Upon Tyne, Tyne & Wear, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 04期
关键词
Immunosuppression; myeloma; infection; plasma cell disorder; monoclonal protein; RISK; THALIDOMIDE; THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE;
D O I
10.1016/j.clml.2021.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunoparesis is associated with poor survival in myeloma (MM). We demonstrate that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. As the depth of IgM immunoparesis impacts survival for hyperdiploid patients, this may be used to further risk-stratify this cytogenetic subgroup of patients for future clinical decisions. Introduction/Background: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes. Materials and Methods: We performed a retrospective review of 985 newly diagnosed patients enrolled in the Myeloma IX and XI trials. Immunoglobulin levels, survival outcomes, and infection rates were evaluated for each cytogenetic subgroup. Results: A significant proportion of patients with high-risk t(4;14), t(14;16), or t(14;20) had suppressed polyclonal immunoglobulins compared to standard-risk patients with hyperdiploidy or t(11;14). The clinical impact of immunoparesis depended on the cytogenetic subgroup, with the degree of IgM suppression effecting progression-free and overall survival only in the hyperdiploid subgroup. There was no significant difference in infection rates amongst the etiologic subgroups. Conclusion: These findings demonstrate that the etiologic cytogenetic subgroup influences the degree and clinical impact of immunoparesis. This suggests that the underlying cytogenetic abnormality affects remodeling of the bone marrow plasma cell niche, resulting in suppressed normal plasma cell function, and low immunoglobulin levels.
引用
收藏
页码:E279 / E284
页数:6
相关论文
共 50 条
  • [42] Prevalence and Prognostic Impact of Cytogenetic Abnormalities in 220 Patients With Multiple Myeloma
    Abe, Yoshiaki
    Fujisawa, Manabu
    Usui, Yoshiaki
    Narita, Kentaro
    Takeuchi, Masami
    Matsue, Kosei
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E29 - E29
  • [43] Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
    Ye, Fang
    Wang, Tongtong
    Liu, Aijun
    Li, Yanchen
    Li, Ningning
    Wang, Huan
    Chen, Wenming
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 246 - 253
  • [44] Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
    Zhang, Yue
    Chen, Xiao-Lei
    Chen, Wen-Ming
    Zhou, He-Bing
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [45] Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
    Nandakumar, Bharat
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis K.
    Lacy, Martha Q.
    Gertz, Morie A.
    Dispenzieri, Angela
    Dingli, David
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Hayman, Suzanne R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Warsame, Rahma M.
    Siddiqui, Mustaqeem A.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2020, 136
  • [46] Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma
    Malave, Gabriella C.
    Kapoor, Prashant
    Dispenzieri, Angela
    Gertz, Morie A.
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Dingli, David
    Buadi, Francis K.
    Muchtar, Eli
    Gonsalves, Wilson I.
    Leung, Nelson
    Go, Ronald S.
    Siddiqui, Mustaqeem
    Kourelis, Taxiarchis
    Warsame, Rahma M.
    Lin, Yi
    Russell, Stephen J.
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [47] Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients
    Mao, Xuehan
    Xu, Yan
    Yan, Yuting
    Liu Jiahui
    Fan Huishou
    Sui Weiwei
    Zengjun, Lizengjun
    Deng, Shuhui
    Yi, Shuhua
    Wang, Tingyu
    Wang, Qi
    Liu, Hui-Min
    Qiu, Lugui
    An, Gang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E83 - E83
  • [48] Association Between Immunoparesis and Treatment Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
    Siwakoti, Ashmita
    Khadka, Sukhdev
    Grimshaw, Alyssa A.
    Giri, Smith
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (11): : e870 - e877
  • [49] A Multi-Center Epidemiological and Prognostic Analysis of Cytogenetic Abnormalities in a Cohort of 1015 Chinese Patients with Newly-Diagnosed Multiple Myeloma
    Jin, Fengyan
    Gao, Guangxun
    Dong, Yujun
    Li, Chunrui
    Huang, Wenrong
    Zhang, Limo
    Zhu, Qiang
    Yuan, Ruifeng
    Xu, Li
    Xu, Yanjie
    Xu, Qian
    Kumar, Shaji K.
    Dai, Yun
    BLOOD, 2019, 134
  • [50] High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation
    Geng, Chuanying
    Lu, Jing
    Li, Xiaozhe
    Li, Qiang
    Li, Na
    Tian, Weiwei
    Zhao, Jie
    Yang, Guangzhong
    Ma, Yanping
    Qin, Xiaoqi
    Jia, Jing
    Zhou, Huixing
    Hi, Lintao
    Wang, Chenchen
    Sun, Ying
    Liu, Xiantao
    Jian, Yuan
    Wang, Qingming
    Wan, Haixiang
    Zhang, Jinqiao
    Liu, Han
    Geng, Hui
    Ma, Xiaojing
    Liang, Yunxia
    Hu, Rui
    Gao, Da
    Han, Donghai
    Liu, Haisheng
    Ma, Guangyu
    Zhang, Zhihua
    Wang, Wei
    Minxia, Shi
    Nie, Bo
    Hong, Zhang
    Li, Jie
    Jie, Guitao
    Fan, Meiying
    Song, Qinglin
    Li, Wenyong
    Xi, Zhenfan
    Gao, Guorong
    Liu, Jie
    Li, Zhihua
    Xue, Hua
    Guo, Huimei
    Li, Jie
    Gao, Xiaohan
    Su, Guo-Hong
    Shen, Jie
    Jin, Aron
    BLOOD, 2024, 144 : 6925 - 6926